SCHEMBL4833889

SCHEMBL4833889

COP(=O)(Cc1ccc(NC(=O)/C=C/c2cnn(C)c2-c2ccc(F)cc2)cc1)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 8/20 0.42
CDK8 P49336 8/20 0.42
CDK19 Q9BWU1 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
MMP1 P03956 3/20 0.38
MMP2 P08253 3/20 0.38
MMP9 P14780 3/20 0.38
EGFR P00533 1/20 0.38
GRM5 P41594 1/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
HPSE Q9Y251 2/20 0.37
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834038 0.92 HDAC1 (0.44) CCNCCDK8CDK19SMN1; SMN2LMNA
SCHEMBL1060125 0.91 BTK (0.41) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4829084 0.91 BTK (0.41) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4829232 0.91 HDAC1 (0.48) SMN1; SMN2NPC1LMNARAB9AHDAC1
SCHEMBL4834311 0.91 HDAC1 (0.45) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4834616 0.91 HDAC1 (0.45) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4829342 0.91 HDAC1 (0.48) SMN1; SMN2NPC1LMNARAB9AHDAC1
SCHEMBL4834010 0.91 CCNC (0.45) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4831284 0.90 CCNC (0.42) CCNCCDK8CDK19SMN1; SMN2NPC1
SCHEMBL4833779 0.90 FLT1 (0.42) CCNCCDK8CDK19SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.